Statin-induced necrotizing autoimmune myopathy. Issue 1 (2nd January 2021)

• Record Type: Journal Article
• Authors: Huda, Syed A.; Yadava, Sanjay; Kahlown, Sara; Farooqi, Muhammad S.; Bryant, Stephanie; Russo, Ronald
• Is Part Of: Proceedings. Volume 34:Issue 1(2021)
• Page Start: 185
• Page End: 186
• Publication Date: 2021-01-02
• Subjects: Immunosuppressants -- rhabdomyolysis -- SINAM -- statin-induced necrotizing autoimmune myopathy -- statins; Medicine -- Periodicals; Medicine; Medicine -- Periodicals; Periodicals; Electronic journals; 616.005
• DOI: 10.1080/08998280.2020.1831298
• Languages: English
• ISSNs: 0899-8280

Abstract

Abstract: Statins are the most widely used class of drug in the United States. They lower blood cholesterol levels by inhibiting 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase. Common side effects include myalgias and a mild increase in liver function tests. Statin-induced necrotizing autoimmune myopathy (SINAM) is a very rare side effect that is independent of the type and duration of statin use. Treatment involves high-dose steroids and immunosuppressants such as azathioprine, methotrexate, or mycophenolate mofetil. Nonresponders and patients with severe weakness can be treated with intravenous immunoglobulin or rituximab. We present a case of SINAM that was successfully treated with intravenous immunoglobulin.